$heff's $tation of $tocks & $olid DD

[north40000]

AMRN: I sent the following via PM to BioHunter last March 15, IMO, it is worth more than "radar":

"I have a large position in Ireland-based Amarin, AMRN. Have you followed at all? Poster zumantu provides daily dd on effects of high omega-3 fatty acids in various disease systems, particularly the fatty acid EPA contained in 96% amount in Amarin's FDA-approved product Vascepa. Narrow label indication so far for reduction of hyper-tryglyceridemia, >500mg/dl.
I have been prescribed Vascepa myself, off-label, by my PCP since 4/1/2013.

You likely are aware of the 2 suits Amarin won against FDA in the SDNY in 2015. The 1st amendment freedom of speech suit[Engenthaler, Judge] recently settled, received wide media attention. Provides for off-label advertising, promotion and marketing with truthful, non mis-leading statements to doctors and hospitals. Its Phase 3 trial of Vascepa should have an interim look by IDMC/DSMB shortly at 967th event.

Its scrips are increasing slowly but surely. Poster sam reports them weekly. Generic Lovaza and other OTC fish oil capsules containing nowhere near 96% EPA are chief competition now, but gL scrips are decreasing while Vascepa scrips are increasing.

The following articles/blogs should help understand the lay of the land. The 1st contains valuable embedded links to variety of background:

http://www.fdalawblog.net/fda_law_blog_hyman_phelps/2016/03/amarin-announces-a-proposed-settlement-of-its-first-amendment-lawsuit-against-fda-coming-full-circle.html?utm_source=feedburner&utm_medium=feed&utm_campaign=Feed%3A+FdaLawBlog+(FDA+Law+Blog)

http://www.skadden.com/insights/amarin-settlement-order-and-vascular-solutions-acquittal-further-erode-label-promotion-enforcement-regime

The court order approving Amarin/FDA settlement:

Court order https://dl.dropboxusercontent.com/u/57678878/AMRN%20Settlement%20.pdf

Personally, I am holding 100k shares for LTCG. The company may be bought out at price greatly exceeding present $1.63. I am betting on this one."
That price was ~ 03-15-2016
I will look to see if I posted a similar one here. My Profile, under My Stocks" may have information similar to above.See also post nos 94185, 94334, the last here:

"AMARIN[AMRN]: 2016 Investors Presentation:

http://files.shareholder.com/downloads/AMRN/3799831906x0x895423/386E7B25-0DE3-47EF-9B4F-AA402B99C6DF/AMRN_IR_Presentation_06072016.pdf

IMO, the slides speak for themselves. Those who understand the technology are well-invested. I have been taking the medication, Vascepa, off-label, since April 2013. I have only a familial history of CVEs from my father's side of the family, and Type 1 diabetes since 1956-7...my mother lived 'til age 92.

It is the other indications discussed in a substantial body of literature that interested me as well as my PCP, a former NIH research physician. The Dry-Eye Syndrome that I used to have disappeared in 3-4 days after beginning Vascepa. I placed a now slightly-outdated drop-box collection of that literature here. Here it is again:

https://dl.dropboxusercontent.com/u/57678878/Compilation%20of%20EPA%20Scientific%20Articles%20.pdf

Not to be forgotten are the 2 pieces of litigation Amarin engaged in with the FDA---Amarin won both in 2015. 1)Its ability to promote and market Vascepa, off label, to physicians and hospitals with truthful and not misleading advertising is now settled. 2)The NCE status of EPA and Vascepa is mentioned in the slides.


AMRN is our 2nd largest holding as an investment. 75% of our shares are currently profitable at current $2.13/share. "